Search results
Results from the WOW.Com Content Network
Since the Monsanto deal closed in mid-2018, Bayer stock has lost 65% of its value, including reinvested dividends, compared with a 56% gain in the pan European healthcare index.
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Bayer’s market cap has fallen more than 44% this year. The group’s $63 billion acquisition of Roundup weed killer parent Monsanto in 2018 has proved disastrous for Bayer, as it faced wave ...
(Bloomberg Opinion) -- Investors aren’t waiting for a definitive deal to end the mass of lawsuits against Bayer AG before snapping up the shares. The German life sciences group’s 75 billion ...
As CEO Bill Anderson wrote for Fortune in an Op-Ed last spring, “Bureaucracy has put Bayer in a stranglehold. Our internal rules for employees span 1,362 pages. Our internal rules for employees ...
Sorafenib, co-developed and co-marketed with Bayer and sold under the trade name Nexavar, is a drug approved in the United States for the treatment of advanced renal cell carcinoma (kidney cancer) in 2005, and for the treatment of inoperable hepatocellular carcinoma, the most common form of liver cancer, in 2007.
Bayer Corporation (also known as Bayer USA) is the American subsidiary of Bayer AG. Its main offices are located in Whippany, New Jersey . In addition it has 40 fully consolidated subsidiary companies [ 3 ] located in 19 different states.
Adverse jury decisions and a pipeline setback have sent Bayer's share price to a nearly 20-year low. Bayer CEO: Corporate bureaucracy belongs in the 19th century. Here’s how we’re fighting it